The investigative team ventured into uncharted territory by subjecting colorectal cancer cells to chronic 5-FU exposure, thereby deriving subpopulations exhibiting acquired drug resistance. Through comprehensive molecular analyses, they identified a significant upregulation of euchromatic histone-lysine N-methyltransferase 2 (EHMT2), an epigenetic regulator implicated in chromatin remodeling and transcriptional repression, within these resistant cancer cells. EHMT2’s known role in gene silencing through histone methylation suggested that its heightened activity could be pivotal in reprogramming cellular pathways to withstand chemotherapeutic stress, prompting the researchers to probe this hypothesis further.

To validate the clinical relevance of EHMT2 upregulation, the study analyzed patient-derived datasets, revealing a stark correlation between elevated EHMT2 expression and diminished responsiveness to 5-FU treatment. Notably, patients exhibiting high EHMT2 activity suffered from significantly reduced overall survival, establishing EHMT2 not merely as a bystander but as a key driver of adverse clinical outcomes in colorectal cancer. This compelling association underscored the urgency of exploring EHMT2 as a therapeutic target capable of overcoming chemoresistance.

Delving into functional assays, the research team employed pharmacologic and genetic approaches to inhibit EHMT2 activity in resistant colorectal cancer cells. Remarkably, suppression of EHMT2 restored cellular sensitivity to 5-FU, manifesting through enhanced induction of apoptosis and marked attenuation of tumorigenic proliferation. Conversely, enforced overexpression of EHMT2 in treatment-naïve cells conferred augmented resistance to 5-FU, confirming EHMT2’s causative role in driving chemoresistance phenotypes. These bidirectional manipulations elegantly demonstrated the protein’s regulatory centrality in modulating therapeutic responses.

Expanding beyond in vitro models, the investigators harnessed patient-derived colorectal cancer organoids and in vivo animal models to mimic the complex tumor microenvironment and disease heterogeneity more faithfully. In these sophisticated systems, combinatorial treatment with 5-FU and an EHMT2-specific inhibitor yielded significant tumor growth suppression, even in organoids and xenografts previously refractory to standard chemotherapy. This translational evidence argued persuasively for a dual therapeutic paradigm that neutralizes resistance while preserving the cytotoxic potency of conventional drugs, potentially circumventing the lengthy and costly process of new drug discovery.

The mechanistic insights suggest that EHMT2 exerts its influence by orchestrating epigenetic modifications that regulate key cellular pathways governing the cell cycle and apoptotic machinery. By methylating histone substrates and repressing transcription of genes essential for cell death, EHMT2 facilitates survival of malignant cells under chemotherapeutic assault. Thus, targeting this epigenetic modulator reinstates the intrinsic apoptotic susceptibility of cancer cells, tipping the balance decisively towards tumor eradication. This epigenetic lens opens a new frontier in understanding and combating drug resistance, one that transcends genetic mutations and taps into reversible chromatin remodeling processes.

Importantly, the implications of this discovery may extend well beyond colorectal cancer. Given that 5-FU remains a staple in the treatment of various malignancies—including gastric, pancreatic, and breast cancers—therapeutic interventions aimed at EHMT2 may offer broad-spectrum benefits across diverse oncology landscapes. This cross-cancer applicability embodies a paradigm shift emphasizing the targeting of epigenetic regulators as a universal strategy to overcome chemoresistance, potentially enhancing the efficacy of existing regimens without resorting to novel cytotoxic agents.

The scientific community stands to gain from this research not only because it identifies EHMT2 as a druggable entity but also because it highlights the nuanced interplay between epigenetics and chemotherapy adaptation. Previous cancer treatments have largely focused on targeting mutated oncogenes or tumor suppressors; this study propels the paradigm towards manipulating chromatin state and gene expression patterns to sensitize tumors. Such an approach may mitigate off-target toxicity and resistance mechanisms tethered to genetic heterogeneity, offering a more refined and sustained therapeutic impact.

Dr. Hyun-Soo Cho underscored the transformative potential of this work: “Our findings illuminate how EHMT2, an epigenetic regulator, empowers colorectal cancer cells to survive chemotherapy. Targeting EHMT2 could fundamentally alter our approach to managing drug resistance, enhancing patient outcomes by revitalizing the efficacy of established treatments.” This visionary perspective galvanizes ongoing research into EHMT2 inhibitors and reinforces the strategic importance of integrating epigenetics into cancer therapy development pipelines.

As the field advances, several avenues invite further exploration, including delineating the specific epigenomic landscapes sculpted by EHMT2 during resistance acquisition, optimizing EHMT2 inhibitors for clinical use, and evaluating combinatory regimens alongside immune checkpoint blockade or other targeted therapies. Moreover, longitudinal patient studies and biomarker development will be critical to stratify patients likely to benefit from EHMT2-targeted interventions and monitor therapeutic response dynamically.

KRIBB’s contribution to this study exemplifies the synergy between cutting-edge biotechnology research and translational oncology, embodying South Korea’s leadership in life sciences innovation. Supported by major national research programs, this collaborative effort harnesses interdisciplinary expertise to address unmet clinical needs, fostering hope for substantially improved colorectal cancer management globally.

In summary, targeting EHMT2 unveils an actionable epigenetic vulnerability underlying 5-FU resistance in colorectal cancer. By reactivating apoptotic pathways and arresting unchecked proliferation, EHMT2 inhibition restores sensitivity to chemotherapy and suppresses tumor progression. This breakthrough not only presents a promising therapeutic avenue but also enriches our fundamental understanding of chemotherapy resistance, heralding a new era in personalized cancer treatment.

Subject of Research: Mechanisms and therapeutic targeting of chemotherapy resistance in colorectal cancer

Article Title: Targeting EHMT2 overcomes 5-fluorouracil resistance in colorectal cancer by modulating cell cycle and apoptosis

News Publication Date: 18-May-2026

Web References: DOI link

Image Credits: Korea Research Institute of Bioscience and Biotechnology (KRIBB)

Keywords: colorectal cancer, 5-fluorouracil resistance, EHMT2, epigenetics, chemotherapy, drug resistance, apoptosis, cell cycle, targeted therapy, cancer epigenomics, therapeutic resistance reversal

Colorectal cancer (CRC) stands as one of the most formidable health challenges globally, afflicting nearly 1.9 million individuals each year. In regions such as Singapore, the incidence remains alarmingly high, underscoring the urgency for novel therapeutic pathways. Traditional chemotherapy protocols have marked successes, yet approximately half of patients develop relapsed or metastatic disease, which undermines long-term survival prospects. This new research pivots on understanding the molecular mechanisms that drive this lethal evolution, focusing intensely on the gene SERPINE1, a previously underappreciated actor in the orchestration of chemoresistance and metastasis.

Utilizing an innovative preclinical model that meticulously replicates clinical chemotherapy dosing regimens, the research team made a serendipitous discovery: resistant cancer cells do not merely endure cytotoxic stress; they actively remodel their biochemical landscape in a manner that fortifies their survival and aggressiveness. This adaptive state is characterized by dysregulated cholesterol biosynthesis and metabolism within the resistant subset of CRC cells—a metabolic reprogramming that signals through and elevates SERPINE1 gene expression. Notably, SERPINE1 encodes plasminogen activator inhibitor-1 (PAI-1), a crucial regulator in the fibrinolytic system, linking coagulation pathways to cancer cell plasticity and invasiveness.

The implications of SERPINE1 hyperactivity extend beyond molecular signaling; analysis of patient tumor samples revealed a robust correlation between heightened SERPINE1 expression and unfavorable clinical outcomes, including increased relapse rates and diminished overall survival. This suggests that SERPINE1 is not merely a biochemical marker but a functional driver of tumor progression. Given these insights, the authors explored therapeutic avenues targeting SERPINE1 along with its upstream pathways.

Strikingly, preclinical interventions that either directly inhibited SERPINE1 or disrupted the altered cholesterol homeostasis—through agents such as statins—restored chemosensitivity to oxaliplatin in resistant tumor models. These combinatorial strategies curtailed metastatic traits and impeded the survival advantage previously acquired by resistant CRC cells. While still in nascent stages, these findings illuminate promising translational pathways, advocating for clinical trials to validate efficacy in patient populations and to potentially redefine standard-of-care for resistant colorectal cancer.

In parallel to uncovering molecular susceptibilities, the multidisciplinary team developed a prognostic gene signature termed RESIST-M. This sophisticated molecular risk score comprises nine genes intricately linked to chemoresistance and metastatic behavior, including SERPINE1. Validation across several independent CRC patient datasets substantiated the predictive power of RESIST-M, demonstrating its ability to stratify patients by risk and forecast relapse propensity with high accuracy.

RESIST-M is particularly enriched in tumors classified as consensus molecular subtype 4 (CMS4), which typifies a highly aggressive colorectal cancer phenotype associated with poor prognosis and challenging clinical management. The ability to identify CMS4 patients who harbor this signature offers a concrete biomarker tool, facilitating tailored treatment approaches and more insightful clinical trial design, while enabling clinicians to monitor disease progression and intervene preemptively.

Central to this discovery was the comprehensive integration of clinical data, genomic profiling, and functional assays. Unlike conventional approaches that rely on supraphysiological drug concentrations, their model more faithfully mimics human chemotherapy exposure, illustrating the adaptive dynamics of tumor evolution under authentic therapeutic pressure. This paradigm shift enhances the clinical relevance of preclinical findings and paves the way for translational breakthroughs.

Dr. Ramanuj DasGupta, Senior Principal Scientist leading the study at A*STAR GIS, emphasized the transformative impact of these findings: “By delineating the biological link between chemotherapy resistance and metastatic potential, we have unveiled biomarkers that not only flag high-risk patients but also suggest clinical interventions to prevent progression before relapse occurs. This could indeed revolutionize the therapeutic landscape of colorectal cancer.”

Supporting this vision, Professor Iain Tan of NCCS underscored the clinical promise: “Aggressive recurrence remains a substantial clinical challenge. The RESIST-M signature empowers clinicians to make more informed, individualized decisions, potentially repurposing existing pharmacological agents, such as statins, to enhance patient outcomes in resistant colorectal cancer.”

Looking ahead, the research consortium is orchestrating clinical trial proposals aimed at evaluating the therapeutic value of targeting SERPINE1 as well as cholesterol metabolism modulators in selected patient cohorts. Further mechanistic studies are planned to decipher why resistant CRC cells downregulate endogenous cholesterol biosynthesis despite the pathway’s apparent role in survival and malignancy, which may uncover additional actionable targets.

Moreover, ongoing endeavors intend to refine and validate RESIST-M as a routine clinical tool, integrating genomic biomarkers into oncology practice to improve patient stratification, enable precision medicine approaches, and optimize trial design for novel therapeutics.

This seminal work exemplifies the power of interdisciplinary research harnessing cutting-edge genomics, molecular biology, and clinical insights to confront the pressing challenge of chemotherapy resistance, offering hope for improved management strategies and patient survival in colorectal cancer.

Subject of Research: Molecular mechanisms and biomarkers of chemotherapy resistance and metastasis in colorectal cancer.

Article Title: [Not explicitly provided in the source material.]

News Publication Date: [Not explicitly stated; publication inferred from journal source.]

Web References:

• Nature Cell Death & Disease Article (DOI: 10.1038/s41419-025-07855-y)

References:

• Study published in Nature Cell Death & Disease, DOI: 10.1038/s41419-025-07855-y.

Image Credits:
[Not specified in the source material.]

Keywords: Colorectal cancer, chemotherapy resistance, SERPINE1, oxaliplatin, cholesterol metabolism, metastasis, RESIST-M signature, precision oncology, statins, cancer biomarkers.